Showing results (1271-1280 of 1,538) with videos related to
Sort By:
Pageof 154
Journal of Geriatric Oncology|March 6, 2021
Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) - an International mRCC Database Consortium (IMDC) analysisDaniel V Araujo, J Connor Wells, Aaron R Hansen, et al.European Urology Oncology|August 15, 2019
Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract CancersNieves Martinez Chanza, Lillian Werner, Elizabeth Plimack, et al.Organic & Biomolecular Chemistry|November 4, 2017
Synthesis and biological assessment of 3,7-dihydroxytropolonesD R Hirsch, D V Schiavone, A J Berkowitz, et al.European Urology|August 7, 2013
Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapyNils Kroeger, Toni K Choueiri, Jae-Lyn Lee, et al.Cancer|May 23, 2013
Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteriaNils Kroeger, Wanling Xie, Jae-Lyn Lee, et al.Human Mutation|May 27, 2015
Microdeletions of ELP4 Are Associated with Language Impairment, Autism Spectrum Disorder, and Mental RetardationLaura Addis, Joo Wook Ahn, Richard Dobson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2020
Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial CancerMatthew D Galsky, Amir Mortazavi, Matthew I Milowsky, et al.British Journal of Cancer|April 3, 2014
First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDCJ J Ko, T K Choueiri, B I Rini, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2024
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell CarcinomaPedro Barata, Catherine Tangen, Melissa Plets, et al.European Urology|May 29, 2024
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) TrialPrimo N Lara, Catherine Tangen, Elisabeth I Heath, et al.Pageof 154